Mitogen-activated protein kinase kinase kinase 14 (MAP3K14) (MAP3K14)

Mitogen-activated protein kinase kinase kinase 14 (MAP3K14), commonly known as NF-kappa-B-inducing kinase (NIK), is a serine/threonine kinase that serves as the central regulator of the non-canonical NF-kappaB signaling pathway (UniProt, 2024). Under normal physiological conditions, NIK protein levels are kept extremely low through continuous proteasomal degradation mediated by a TRAF2/TRAF3/cIAP ubiquitin ligase complex (NIH, 2025). Upon stimulation by specific ligands such as BAFF, CD40L, or TWEAK, NIK is stabilized and accumulates, leading to the phosphorylation and activation of IKK-alpha (OncoKB, 2024). This activation triggers the proteolytic processing of p100 into the active p52 subunit, which then translocates to the nucleus to regulate genes involved in B-cell maturation, lymphoid organogenesis, and inflammation (UniProt, 2024). Dysregulation or overexpression of NIK is strongly associated with various pathologies, including B-cell malignancies like multiple myeloma and Hodgkin lymphoma, as well as autoimmune and inflammatory disorders such as lupus and rheumatoid arthritis (NIH, 2025). Consequently, NIK has emerged as a promising therapeutic target, with several small-molecule inhibitors currently in development designed to block its kinase activity and suppress aberrant non-canonical NF-kappaB signaling (NIH, 2025). These inhibitors typically target the ATP-binding pocket of the kinase domain to prevent downstream signaling (NIH, 2025). However, therapeutic intervention must be carefully managed due to the essential role of NIK in maintaining normal immune function and lymphoid architecture (NIH, 2025).

Other names

NF-kappa-B-inducing kinaseNIKHSSTK2FTDCR1B

Inhibition of the catalytic ATP-binding site of NIK, preventing the phosphorylation of IKK-alpha and subsequent processing of p100 to p52 in the non-canonical NF-kappaB pathway (NIH, 2025).